Gilead Ordered to Give Files to Investors Weighing Truvada Suit

Gilead Sciences Inc. investors easily proved they’re entitled to examine its records as they consider suing over business practices related to its blockbuster HIV drug Truvada, a Delaware Chancery Court judge ruled, saying the company’s arguments “border on absurd” and threatening to hit it with attorneys’ fees.

“The complaint tells a story as replete with inequity as the biblical verse that the company’s namesake brings to mind,” and Gilead’s “peripheral attacks” offer “no principled grounds for categorically disregarding” allegations from other court cases facing the drugmaker, Vice Chancellor Kathaleen S. McCormick wrote.

“Gilead’s overly aggressive defense strategy epitomizes a trend,” ...